datetime,headline,summary,related,lang,source
2020-12-09 02:13:12-05:00,"Preventive Healthcare Technologies And Services Market With Covid 19 Impact Analysis | Key Players: Omnicell Inc., Merck & Co. Inc., McKesson Corporation, GlaxoSmithKline plc., Medtronic, Quest Diagnostics Inc., Alere, Myriad Genetics Inc.","The Preventive Healthcare Technologies And Services Market (2020) research report explores the market in terms of Revenue And Emerging Market Trends and Drivers and includes an up to date analysis and forecasts for various market segments, major players, and all",MYD,en,OpenPR
2020-12-02 03:27:28-05:00,"Companion Diagnostics Market Impact Of covid19 - Abbott Laboratories, Agilent Technologies Inc., Danaher Corporation, Qiagen N.V., F. Hoffmann-La Roche AG, bioMerieux S.A., Illumina, Inc., GE Healthcare, Myriad Genetics Inc., and Siemens Healthineers.",An informative study on the Companion Diagnostics Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top regions and countries,MYD,en,OpenPR
2020-11-24 07:31:12-05:00,"PARP Inhibitor Biomarkers Market - Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.",An informative study on the PARP Inhibitor Biomarkers Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top regions and,"MYD,MYGN",en,OpenPR
2020-11-17 07:10:11-05:00,"Consumer Genomics Market : COVID-19 Impact Analysis with Size, Share, Industry Outlook and Future Scope, Leading Players are Gene by Gene, Veritas Genetics, Myriad Genetics, Toolbox Genomics, QIAGEN, Eurofins Scientific","Analysis and discussion of important industry trends, market size, and market share estimates are revealed in the Consumer Genomics Market research report. Further, manufacturer can adjust production according to the conditions of demand which are analyzed here. The report aids","MYD,MYGN",en,OpenPR
2020-11-16 09:09:16-05:00,"Direct-to-consumer Genetic Testing Market Share and SWOT Analysis: Myriad Genetics Inc., 23andMe Inc., Invitae, Ambry Genetics","The Direct-to-consumer Genetic Testing market report gives an in-depth analysis of the global market where it includes drivers, restraints, and trends, and opportunities contributing in the growth of the market. The Direct-to-consumer Genetic Testing report also consists of geographical analysis","MYD,MYGN",en,OpenPR
2020-11-16 07:05:00-05:00,Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China - Stocks News Feed,"SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice® tumor testing in several European markets and China. Myriad myChoice CDx is the industry’s most clinically-validated genomic instability test. The test enables physicians to identify… Read More »Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China","MYD,MYGN",en,Stocks News Feed
2020-11-09 09:39:00-05:00,Myriad Genetics Earnings and Growth Analysis : Stock market Insights & financial analysis,"Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…","MYD,MYGN",en,Stock Market Daily
2020-11-08 17:35:42-05:00,Myriad Genetics Q1 2021 Earnings Preview (NASDAQ:MYGN),"Myriad Genetics (NASDAQ:MYGN) is scheduled to announce Q1 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate is -$0.3","MYD,MYGN",en,Seeking Alpha
2020-10-27 07:23:49-05:00,"Liquid Biopsy Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, Genomic Health, RainDance Technologies","This Liquid Biopsy Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as","MYD,MYGN",en,OpenPR
2020-10-23 05:30:43-05:00,Myriad Genetics (NASDAQ:MYGN) Stock Price Up 5.1%,"Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) rose 5.1% on Wednesday . The company traded as high as $14.07 and last traded at $14.02. Approximately 635,557 shares changed hands during trading, a decline of 37% from the average daily volume of 1,013,374 shares. The stock had previously closed at $13.34. MYGN has been the topic of […]","MYD,MYGN",en,Zolmax News
2020-10-22 04:04:47-05:00,Financial Analysis: Myriad Genetics (NASDAQ:MYGN) & Navidea Biopharmaceuticals (NASDAQ:NAVB),"Myriad Genetics (NASDAQ:MYGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Profitability This table compares Myriad Genetics and Navidea Biopharmaceuticals’ net margins, return on equity and […]","MYD,MYGN,NAVB",en, Dakota Financial News
2020-10-21 12:56:58-05:00,Myriad Genetics (NASDAQ:MYGN) Trading 5.1% Higher,"Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) traded up 5.1% during mid-day trading on Wednesday . The company traded as high as $14.07 and last traded at $14.02. 635,557 shares traded hands during trading, a decline of 37% from the average session volume of 1,013,374 shares. The stock had previously closed at $13.34. A number of […]","MYD,MYGN",en,US Banking News
2020-10-19 22:52:41-05:00,Myriad Genetics (NASDAQ:MYGN) Cut to Sell at BidaskClub,"BidaskClub lowered shares of Myriad Genetics (NASDAQ:MYGN) from a hold rating to a sell rating in a research note released on Friday morning, BidAskClub reports. Several other equities research analysts have also weighed in on MYGN. Needham & Company LLC reaffirmed a hold rating on shares of Myriad Genetics in a report on Friday, August […]","MYD,MYGN",en,Stock Observer
2020-10-08 19:15:00-05:00,"Genetic Testing Market to reach $ 4.86 bn by 2024, Abbott Laboratories, Agilent Technologies Inc., and Thermo Fisher Scientific Inc., emerge as Key Contributors to growth | Technavio","Technavio has been monitoring the genetic testing market and it is poised to grow by $ 4.86 bn during 2020-2024, progressing at a CAGR of over 12% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005738/en/ Technavio has announced its latest market research report titled Global Genetic Testing Market 2020-2024 (Graphic: Business Wire) Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio's in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.","MYGN,MYD",en,Benzinga
2020-10-08 11:49:21-05:00,"Liquid Biopsy Market (COVID - 19 Updates) Complete Survey 2020 Insights, Demand, Analysis, Type, Size and Share, Leading Players are Immucor, Thermo Fisher Scientific, QIAGEN, Myriad Genetics, Natera, Genomic Health","This Liquid Biopsy Market research report is a detailed synopsis on the study of industry and its impact on the market environment. By systematically understanding and keeping into thought customer requirement, one step or combination of many steps has been","MYGN,MYD",en,OpenPR
2020-10-06 09:25:55-05:00,"Liquid Biopsy Market 2020 with Impact of COVID-19 Pandemic Analysis & Future Growth Analysis Report, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, LungLife AI, Bio-Rad Laboratories, Natera","When globalization is growing day by day, many businesses call for global market research consisting of actionable market insights that helps with decision making. This Liquid Biopsy Market analysis report gives out the data for industry about company profile, product","MYGN,MYD",en,OpenPR
2020-10-05 06:04:54-05:00,"COVID-19 UPDATE: Clinical Oncology Next Generation Sequencing Market Likely to Experience a Tremendous Growth in Near Future|| Illumina Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Thermo Fisher Scientific, Myriad Genetics Inc",Data Bridge Market Research has recently added a concise research on the Clinical Oncology Next Generation Sequencing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted,"MYD,MYGN",en,OpenPR
2020-10-01 02:17:22-05:00,"Global Clinical Oncology Next Generation Sequencing Market At A CAGR Of 13.90% Growth, Trends And Absolute Opportunity Up To 2027||Thermo Fisher Scientific, Myriad Genetics Inc., BGI, Perkin Elmer, Inc., Exosome Diagnostics Inc., GATC Biotech, DNASTAR, Qi",Data Bridge Market Research has recently added a concise research on the Clinical Oncology Next Generation Sequencing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges,"MYD,MYGN",en,OpenPR
2020-09-30 05:06:34-05:00,"Direct-to-consumer Genetic Testing Market 2020-2026: Key Vendor Landscape By Regional Output, Demand By Countries And Future Growth(MyHeritage, LabCorp, Myriad Genetics)","Los Angeles, United State, – – QY Research recently added a research report, Global Direct-to-consumer Genetic Testing Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Direct-to-consumer Genetic Testing market. It highlights","MYD,MYGN",en,OpenPR
2020-08-14 15:05:00-05:00,Myriad Genetics Announces Inducement Awards,"SALT LAKE CITY, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular…","MYD,MYGN",en,GlobeNewswire
2020-08-13 10:31:00-05:00,"Global Genomics Market Outlook 2020-2025; Dominated by Illumina, Thermo Fisher Scientific, Agilent Technologies, Luminex Corporation and Myriad Genetics - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Genomics Market - Growth, Trends, and Forecasts (2020-2025)"" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Market is anticipated to grow at a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the genomics market are growing government support and increased number of genomics studies, declining sequencing cost, increased genomics applications. The genomics market is geared to exponential growth","MYD,MYGN",en,Business Wire
2020-07-22 06:05:00-05:00,"Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.","Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of…","MYD,MYGN",en,GlobeNewswire
2020-07-15 11:21:36-05:00,"Inmedix welcomes Bernie Tobin, former President of Crescendo Bioscience (Myriad Genetics) to its Board of Directors","Seasoned biotech leadership expected to bolster the launch of bloodless, cloud-based, clinical diagnostics at Inmedix, Inc.","MYD,MYGN",en,EIN News
2020-07-06 07:28:59-05:00,Myriad partners with OptraHealth for AI based information tool for hereditary cancer patients (NASDAQ:MYGN),Myriad Genetics (NASDAQ:MYGN) partners with OptraHEALTH to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance informatio,"MYD,MYGN",en,Seeking Alpha
2020-06-09 09:23:00-05:00,Myriad Genetics' Test Better Predicts Drug Levels Per Study,Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.,"MYGN,MYD",en,Zacks Investment Research
2020-06-04 10:31:31-05:00,Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report?,Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,"MYGN,MYD",en,Zacks Investment Research
2020-06-04 06:05:00-05:00,Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer,EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy,"MYGN,MYD",en,GlobeNewswire
2020-05-27 10:14:00-05:00,"Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories","Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories","MYGN,MYD",en,Zacks Investment Research
2020-05-18 10:55:00-05:00,Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem,"Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.","MYGN,MYD",en,Zacks Investment Research
2020-05-06 10:49:00-05:00,"Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View",Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.,"MYGN,MYD",en,Zacks Investment Research
2020-04-07 15:26:29-05:00,Shared-Use Space For Cannabis Manufacturing To Debut In Southern California,"My Green Network (MyGN) is set to open a membership-based, entrepreneur-focused, collaborative cannabis facility inin Orange County, California this summer. The company promises to provide “a home, a network, compliance and access to cannabis verticals.” Who Is It For? Average cannabis startup costs are getting higher by the minute. MyGN aims to reduce these costs substantially by helping entrepreneurs target six main barriers: Money Compliance Property Time Experience Legal Uncertainty Founded by attorneys Ken Hwang and James Shih, and visionary brand strategist, Maria Cordeiro, MyGN will focus on fostering a … Full story available on Benzinga.com","MYD,MYGN",en,Benzinga Feeds
2020-04-07 08:32:00-05:00,Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement,"Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.","MYD,MYGN",en,Zacks Investment Research
2020-03-19 08:46:00-05:00,"Myriad Grows Internationally, Hereditary Cancer Revenues Soft","Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.","MYD,MYGN",en,Zacks Investment Research
2020-03-16 18:40:09-05:00,Myriad Genetics : A letter from Bryan Riggsbee | MarketScreener,"March 16, 2020 Dear Customer, At Myriad, we are actively monitoring the COVID-19/Coronavirus situation and have implemented a business… | March 17, 2020","MYD,MYGN",en,MarketScreener
2020-03-11 07:03:52-05:00,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.","MYD,MYGN",en,Benzinga
2020-03-07 11:31:00-05:00,Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound?,Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,"MYD,MYGN",en,Zacks Investment Research
2020-03-04 08:29:00-05:00,"Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems","Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems","MYD,MYGN",en,Zacks Investment Research
2020-02-28 06:58:00-05:00,"The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher","The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher","MYD,MYGN",en,Zacks Investment Research
2020-02-27 07:35:07-05:00,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.","MYD,MYGN",en,Benzinga
2020-02-25 08:28:09-05:00,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Co-Diagnostics Inc (NASDAQ: CODX )(received CE mark for its coronavirus test) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) Gilead Sciences, Inc. (NASDAQ: GILD )(reacted to a statement from WHO that its experimental drug remdesivir could be the one drug that may have efficacy) NGM Biopharmaceuticals Inc (NASDAQ: NGM )( reacted to positive readout for its NASH drug) PAVmed Inc (NASDAQ: PAVM ) TELA Bio Inc (NASDAQ: TELA ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 24) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) AngioDynamics, Inc. (NASDAQ: ANGO ) BioSig Technologies Inc (NASDAQ: BSGM ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc.","MYD,MYGN",en,Benzinga
2020-02-17 01:46:00-05:00,Myriad Genetics (MYGN) Releases Favorable Prolaris Results,This study result is a major breakthrough and is expected to strengthen Myriad Genetics' (MYGN) Oncology segment.,"MYD,MYGN",en,Zacks Investment Research
2020-02-13 10:36:00-05:00,Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA,"With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.","MYD,MYGN",en,Zacks Investment Research
2020-02-07 20:08:00-05:00,"The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Myriad Genetics, Inc., Investors (MYGN)","LOS ANGELES--(BUSINESS WIRE)---- $MYGN #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Myriad Genetics, Inc., (“Myriad” or the “Company”) (NASDAQ: MYGN) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you own Myriad shares and wish to discuss this matter with us, or have any questions concerning your rights and int","MYD,MYGN",en,Business Wire
2020-02-07 09:56:00-05:00,Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates,"Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.","MYD,MYGN",en,Zacks Investment Research
2020-02-07 08:58:00-05:00,Myriad Genetics Stock Is Tanking After Earnings. The CEO Is Out.,The stock was down by nearly one-third in premarket trading as earnings fell short of Wall Street’s expectations. CEO Mark Capone is resigning.,"MYD,MYGN",en,MarketWatch
2020-02-07 07:32:45-05:00,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ALEC ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Beam Therapeutics Inc (NASDAQ: BEAM ) (IPOed Thursday) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Insmed Incorporated (NASDAQ: INSM ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) PPD Inc (NASDAQ: PPD ) (IPOed Thursday) Principia Biopharma Inc (NASDAQ: PRNB ) Profound Medical Corp (NASDAQ: PROF ) PTC Therapeutics, Inc (NASDAQ: PTCT ) ResMed Inc. (NYSE: RMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced FDA acceptance of BLA for DAXI to treat frown lines) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb.","MYD,MYGN",en,Benzinga
2020-02-06 18:15:07-05:00,Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates,"Myriad (MYGN) delivered earnings and revenue surprises of -25.81% and -6.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?","MYD,MYGN",en,Zacks Investment Research
2020-01-29 12:00:00-05:00,"$22.5Bn+ Molecular Diagnostics Market Insights, 2025 - Featuring Company Analysis of Roche Diagnostics, Abbott Laboratories, Myriad Genetics, Qiagen, and bioMerieux","/PRNewswire/ -- The ""Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies"" report has been added to…","MYD,MYGN",en,PR Newswire
2020-01-28 12:31:31-05:00,Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline,Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"MYD,MYGN",en,Zacks Investment Research
2020-01-16 06:01:00-05:00,"Global Molecular Diagnostics Market, 2020 - Agilent Technologies, Diadexus, Exact Sciences, Myriad Genetics & Qiagen - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""2020 Global Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies"" report has been added to ResearchAndMarkets.com's offering. This unique report from the author provides sales and market share estimates for major suppliers of molecular diagnostic products by country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, m","MYD,MYGN",en,Business Wire
2020-01-12 12:47:00-05:00,WSJ News Exclusive | Geneticists Call on Myriad to Share Proprietary Data to Aid Gene Tests,A leading medical society is calling on Myriad Genetics and other lab companies to share proprietary genetic testing data in a public database.,"MYD,MYGN",en,The Wall Street Journal
2020-01-07 03:35:00-05:00,Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging,The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.,"MYD,MYGN",en,Zacks Investment Research
2019-12-31 05:12:00-05:00,Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod,Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.,"MYD,MYGN",en,Zacks Investment Research
2019-12-30 12:37:00-05:00,INVESTOR ALERT: Kirby McInerney LLP Launches Investigation of Myriad Genetics (MYGN) for Possible Breaches of Fiduciary Duty by Certain Officers and Directors,"NEW YORK--(BUSINESS WIRE)-- #classaction--The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN). The investigation relates to possible breaches of fiduciary duty by certain officers and directors of the Company. In July 2019, the Company paid $9.1 million to resolve claims brought by a whistleblower that formed the basis for a subpoena issued by the U.S. Department of Health and Human Services Office of Inspector General t","MYD,MYGN",en,Business Wire
2019-12-30 08:54:06-05:00,Myriad Genetics Spikes on FDA Approval of Pancreatic Cancer Diagnostic Test,"The FDA approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.","MYD,MYGN",en,The Street
2019-12-30 08:41:00-05:00,"Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground",Futures on the Dow Jones Industrial Average and other major U.S. stock indexes pointed to small gains.,"MYD,MYGN",en,Barron's
2019-12-30 07:45:00-05:00,Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer,"Share of Myriad Genetics Inc. shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the…","MYD,MYGN",en,MarketWatch
2019-12-23 14:42:00-05:00,Myriad Genetics Is Tumbling After The Wall Street Journal Highlighted the Risks of Acting on Genetic Testing,"Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.","MYD,MYGN",en,Barron's
2019-12-05 03:24:00-05:00,Myriad Genetics Reports Favorable Study Result on Prequel,"Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.","MYD,MYGN",en,Zacks Investment Research
2019-12-04 11:30:50-05:00,Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?,Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,"MYD,MYGN",en,Zacks Investment Research
2019-11-25 20:00:00-05:00,"MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action","NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. from September 2, 2016 through August 13, 2019, inclusive (the ""Class Period"") of the important November 26, 2019 lead plaintiff…","MYD,MYGN",en,PR Newswire
2019-11-25 09:03:00-05:00,Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan,"The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.","MYD,MYGN",en,Zacks Investment Research
2019-11-22 10:01:00-05:00,Myriad Genetics' Test Added in Disease Activity Measure List,"Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.","MYD,MYGN",en,Zacks Investment Research
2019-11-20 18:15:00-05:00,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm","NEW YORK--(BUSINESS WIRE)-- #MYGN--Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Myriad Genetics, Inc. (NASDAQ: MYGN) securities between September 2, 2016 to August 13, 2019 (the “Class Period”). Investors have until November 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click h","MYD,MYGN",en,Business Wire
2019-11-07 13:00:43-05:00,Myriad Genetics (NASDAQ:MYGN) Issues Q2 Earnings Guidance,"Myriad Genetics (NASDAQ:MYGN) issued an update on its second quarter earnings guidance on Monday morning. The company provided EPS guidance of $0.30-0.32 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.47. The company issued revenue guidance of $210-212 million, compared to the consensus revenue estimate of $220.57 million.Myriad Genetics also updated […]","MYD,MYGN",en,Modern Readers
2019-11-05 08:57:00-05:00,Myriad Genetics Stock Is Sinking After It Missed on Earnings and Cut Guidance,"The company said it now expects between $800 million and $810 million in revenue in the 2020 fiscal year, far less than the $865 million to $875 million range it had previously projected.","MYD,MYGN",en,Barron's
2019-11-05 08:09:00-05:00,Myriad Genetics stock plunges to lead premarket losers after earnings miss by wide margin,"Shares of Myriad Genetics Inc. plummeted 35% to pace all premarket decliners, after the molecular diagnostics company reported fiscal first-quarter results…","MYD,MYGN",en,MarketWatch
2019-10-29 09:33:25-05:00,Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for,Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"MYD,MYGN",en,Zacks Investment Research
2019-10-28 10:24:00-05:00,Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod,"Myriad Genetics (MYGN) moves a step toward advanced treatment by identifying women with ovarian cancer, who are currently receiving chemotherapy.","MYD,MYGN",en,Zacks Investment Research
2019-10-07 16:00:00-05:00,Summit Hotel Properties Announces Pending Acquisition Of West Coast Portfolio For $249 Million,"AUSTIN, Texas , Oct. 7, 2019 /PRNewswire/ -- Summit Hotel Properties, Inc. (NYSE: INN ) (the ""Company"") today announced that it has entered into a definitive agreement to acquire four hotels located on the west coast for $249 million through its recently formed joint venture with GIC. The high-quality portfolio is located in three high-growth markets and includes the 258-guestroom Residence Inn by Marriott Portland Downtown/RiverPlace, the 169-guestroom Hilton Garden Inn San Francisco Airport North, the 161-guestroom Hilton Garden Inn San Jose/Milpitas, and the 122-guestroom Residence Inn by Marriott Portland Hillsboro . The total purchase price of $249 million , or approximately $351,000 per key, represents an average capitalization rate of 8.4 percent based on management's current estimate of the hotels' net operating income for the full-year 2019. With an average RevPAR of $162 and average hotel EBITDA margin of over 50 percent, the pending acquisitions will further enhance the Company's diverse portfolio of well-located hotels with efficient operating models.","MYD,MYGN",en,Benzinga
2019-09-26 10:35:00-05:00,"Myriad Genetics Stock’s Wild Ride Will Continue, Analyst Says","Analysts at Bank of America/Merrill Lynch are backing away from Myriad Genetics, as the stock continues its jagged path of the past few months.","MYD,MYGN",en,Barron's
2019-09-12 08:30:05-05:00,Myriad (MYGN) Up 5.9% Since Last Earnings Report: Can It Continue?,Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,"MYD,MYGN",en,Zacks Investment Research
2019-09-08 18:23:13-05:00,Here's Why Myriad Genetics Dropped 19.2% in August | The Motley Fool,The genetic testing leader took investors on a wild ride last month.,"MYD,MYGN",en,The Motley Fool
2019-09-04 11:40:00-05:00,Myriad Executives Sold Stock Before Shares Plunged,CEO Capone and other executives sold $10 million of shares on Aug. 1 through trading plans. Myriad Genetics stock dove after an Aug. 13 conference call in which the company said that its key new product GeneSight was in hot water with the FDA.,"MYD,MYGN",en,Barron's
2019-08-16 19:26:00-05:00,Myriad Genetics Stock Has an F.D.A. Issue,A test that Myriad is counting on to restore sales growth is in trouble with the U.S. Food and Drug Administration.,"MYD,MYGN",en,Barron's
2019-08-14 09:33:00-05:00,"Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questions",Shares of molecular-diagnostics firm Myriad Genetics Inc. plummeted 39% Wednesday morning after the company reported lower-than-expected fourth-quarter…,"MYD,MYGN",en,MarketWatch
2019-08-14 09:18:00-05:00,Pioneering genetic-testing company Myriad's biggest new product is facing pushback from US regulators that could 'significantly limit' the test's appeal. The stock is down 40%. (MYGN),"Pioneering genetic-testing company Myriad Genetics sells a test called GeneSight that claims to analyze a patient's DNA and point them to the best depression drug for them. Scientists and doctors have raised concerns about GeneSight and other similar tests. Now, the FDA is asking for changes to GeneSight, Myriad Genetics disclosed on Tuesday. Those changes ""could significantly limit"" broad adoption of GeneSight because it would not be able to make specific drug recommendations, JPMorgan analyst Tycho Peterson and team said. This news comes after UnitedHealth Group, the nation's largest health insurer, said it would start covering GeneSight and other such tests for certain patients starting in October. Myriad Genetics stock dropped nearly 40% in Wednesday morning trade. Click here for more BI Prime stories. Genetic-testing company Myriad Genetics's biggest up-and-coming product is a test that claims to match patients with depression to the best medications for them, based on their DNA. ","MYD,MYGN",en,Business Insider
2019-08-14 07:55:00-05:00,Myriad Genetics Stock Craters on Weak Earnings and FDA Scrutiny,Shares of the molecular-diagnostic biotech firm were down 30.4% after the company reported financial results that missed expectations and it said the FDA had “requested changes” to GeneSight.,"MYD,MYGN",en,MarketWatch
2019-08-13 16:35:04-05:00,Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates,"Myriad (MYGN) delivered earnings and revenue surprises of -12.77% and -2.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?","MYD,MYGN",en,Zacks Investment Research
2019-08-01 12:36:28-05:00,Myriad Genetics Shares Jump To 9-Month High On Insurance Coverage For Genetic Test,"Shares of molecular diagnostics company Myriad Genetics, Inc. (NASDAQ: MYGN ) were rallying to a nine-month high Thursday on above-average volume. Myriad shares are reacting to a decision by UnitedHealth Group Inc (NYSE: UNH ) to cover pharmacogenetic testing … Full story available on Benzinga.com","MYD,MYGN",en,Benzinga
2019-07-16 10:12:00-05:00,Here's what Kroger stands to gain from its new partnership with Myriad Genetics (KR),"This is an excerpt from a story delivered exclusively to Business Insider Intelligence Digital Health Pro subscribers. To receive the full story plus other insights each morning, click here. Grocery store chain Kroger announced it's teaming up with Salt Lake City-based genetic testing company Myriad Genetics to bring the company's GeneSight test to select members of Kroger's employee health plan, per MedCity News. Myriad's GeneSight test screens an individual for genetic markers that would indicate a more favorable response to certain behavioral health medications. The pilot program will be available at nearly 500 Kroger pharmacies to Health Plan members who've been unsuccessfully treated with one or more antidepressant medications. Here's what it means: Kroger is experimenting with Myriad's genetic screening for Health Plan members to reduce the cost of providing health coverage to its massive workforce. Kroger is struggling to secure its financial footing — and claims inefficiencies in its health plan are part of the problem.","MYD,MYGN",en,Business Insider
2019-07-10 07:23:00-05:00,Kroger Health teams up with Myriad Genetics on gene-testing pilot,"Kroger Health, Kroger Co's health-care arm, is teaming up with Myriad Genetics to carry out a pilot of a genetic test meant to help clinicians personalize…","MYD,MYGN",en,MarketWatch
2019-07-09 08:34:00-05:00,Myriad Genetics Stock Is Falling as Enthusiasm Wanes,"Cowen analyst Doug Schenkel downgraded Myriad to Market Perform from Outperform, and dropped his price target on the stock to $30 from $37.","MYD,MYGN",en,Barron's
2019-06-26 06:19:56-05:00,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 25) AbbVie Inc (NYSE: ABBV )(announced a deal to buy Allergan plc (NYSE: AGN ) for $63 billion) Acer Therapeutics Inc (NASDAQ: ACER )(The FDA issued complete response letter to its rare disease drug Edsivo) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aldeyra Therapeutics Inc (NASDAQ: ALDX )( reported negative results for the late-stage study that evaluated its reproxalap in anterior uveitis) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Axcella Health Inc (NASDAQ: AXLA ) Biopharmx Corp NYSE: (BPMX) (reported positive results for a Phase 2b clinical trial of BPX-04 in treating moderate-to-severe papulopustular rosacea) CELYAD SA/ADR (NASDAQ: CYAD ) Conatus Pharmaceuticals Inc (NASDAQ: CNAT )( announced decision to explore strategic alternatives following failed NASH drug trial) Enochian Biosciences Inc (NASDAQ: ENOB ) Evolent Health Inc (NYSE: EVH ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Myriad Genetics, Inc.","MYD,MYGN",en,Benzinga
2019-06-06 08:31:17-05:00,Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?,Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,"MYD,MYGN",en,Zacks Investment Research
2019-06-03 03:03:00-05:00,Myriad Genetics' (MYGN) POLO Study Shows Positive Results,Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.,"MYD,MYGN",en,Zacks Investment Research
2019-05-21 02:14:00-05:00,Why Should You Hold on to Myriad Genetics (MYGN) Stock?,Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).,"MYD,MYGN",en,Zacks Investment Research
2019-05-15 17:16:19-05:00,Guardant Health: Competitors Are Trading At Cheaper Valuations,No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-05-15 07:15:00-05:00,"Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?",The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.,"MYD,MYGN",en,The Motley Fool
2019-05-08 15:53:51-05:00,"Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today",These stocks struggled on a mixed day on Wall Street.,"MYD,MYGN",en,The Motley Fool
2019-05-08 11:06:33-05:00,"Myriad Genetics down 22% on FQ3 revenue miss, softer guidance",Myriad Genetics ([[MYGN]] -21.8%) slumps on triple normal volume following its fiscal Q3 report released after the close yesterday. Highlights: Revenue up,"MYD,MYGN",en,Seeking Alpha
2019-05-08 08:24:08-05:00,Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript,"MYGN earnings call for the period ending March 31, 2019.","MYD,MYGN",en,The Motley Fool
2019-05-08 01:56:00-05:00,"Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up","Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.","MYD,MYGN",en,Zacks Investment Research
2019-05-07 19:06:10-05:00,"Myriad Genetics, Inc. 2019 Q3 - Results - Earnings Call Slides","The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2019 Q3 earnings call.","MYD,MYGN",en,Seeking Alpha
2019-05-07 15:09:09-05:00,"Myriad Genetics beats by $0.03, misses on revenue",No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-05-06 16:10:09-05:00,"Notable Monday Option Activity: MYGN, PANW, EBIX",Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Myriad Genetics Inc Symbol MYGN where a total volume of 2 320 contracts has been traded thus far today a contract volume which is representative of approximately 232,"MYD,MYGN",en,Nasdaq
2019-05-01 15:05:00-05:00,Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®,"SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide GeneSight ® as an benefit option for Kroger Prescription Plan employer group clients. Additionally, pharmacists at more than 2,300 Kroger stores will provide counselling about GeneSight to eligible employer group members and facilitate testing with their prescribing healthcare professionals. ""Major depressive disorder is a common, disabling and costly mental illness. We are excited to support new interventions such as genetic testing that are aimed at helping people find the right medication,"" said Rich Adams, senior vice president at Kroger Prescription Plans. ""We believe the GeneSight test provides valuable genetic information that potentially can lead to transformative care for our members with depression and help them get well sooner."" ""We are excited to expand our relationship with Kroger Prescription Plans,"" said Chip Parkinson, executive vice president of Payer Markets at Myriad Genetics. ""Increasingly, employers are at the forefront of improving employee wellness, particularly when it comes to mental health illnesses, and reducing their healthcare costs."" In July 2018, Myriad announced that Kroger Prescription Plans will provide Vectra ® as a benefit option for Kroger Prescription Plan employer group clients.","MYD,MYGN",en,Benzinga
2019-05-01 02:05:00-05:00,Myriad Genetics to Present at Two Upcoming Healthcare Conferences,"SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced …","MYD,MYGN",en,Benzinga
2019-04-23 11:05:00-05:00,"Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019","SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in personalized medicine, today announced that it will hold …",MYD,en,Benzinga
2019-04-09 06:56:57-05:00,Myriad submits PMA for myChoice HRD CDx test,Myriad Genetics (MYGN) has submitted the first module of its premarket approval ((PMA)) application to the FDA for its myChoice HRD CDx test. The submissio,"MYD,MYGN",en,Seeking Alpha
2019-04-04 07:56:00-05:00,Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake,The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.,"MYD,MYGN",en,Zacks Investment Research
2019-03-28 05:16:00-05:00,"Myriad Genetics Gains on Innovation, New Reimbursements","Myriad Genetics (MYGN) aims at raising revenues by commercializing its product suite that includes Vectra DA, Prolaris, myPath Melanoma, Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test.","MYD,MYGN",en,Zacks Investment Research
2019-03-18 03:03:00-05:00,Myriad's myPath Melanoma Test Awarded Medicare Coverage,The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.,"MYD,MYGN",en,Zacks Investment Research
2019-03-14 15:27:21-05:00,"Health Care Sector Update for 03/14/2019: MYGN,MLNT,SPHS,AXGT",Top Health Care StocksTop Health Care Stocks JNJ 0 74 JNJ 0 74 PFE 1 87 PFE 1 87 ABT 0 46 ABT 0 46 MRK 0 32 MRK 0 32 AMGN 0 03 AMGN 0 03 Health care stocks extended their declines this afternoon including a slightly more than 0 2 decline for the NYSE Health Care Index Shares,"MYD,MYGN",en,Nasdaq
2019-03-14 15:27:21-05:00,"Health Care Sector Update for 03/14/2019: MYGN,MLNT,SPHS,AXGT",Top Health Care StocksTop Health Care Stocks JNJ 0 74 JNJ 0 74 PFE 1 87 PFE 1 87 ABT 0 46 ABT 0 46 MRK 0 32 MRK 0 32 AMGN 0 03 AMGN 0 03 Health care stocks extended their declines this afternoon including a slightly more than 0 2 decline for the NYSE Health Care Index Shares,MYD,en,Nasdaq
2019-02-26 13:56:50-05:00,Myriad Genetics touts value of BRACAnalysis CDx in successful pancreatic cancer study,No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-02-26 13:56:50-05:00,Myriad Genetics touts value of BRACAnalysis CDx in successful pancreatic cancer study,No summary available.,MYD,en,Seeking Alpha
2019-02-09 09:46:30-05:00,Stocks To Watch: Those Ticking Clocks,No summary available.,"MYD,MYGN,MU,MTSI,MYL,MXIM",en,Seeking Alpha
2019-02-06 13:39:04-05:00,Myriad Genetics up 7% after FQ2 report,No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-02-06 00:22:05-05:00,"Myriad Genetics, Inc. (MYGN) CEO Mark Capone on Q2 2019 Results - Earnings Call Transcript",No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-02-05 16:06:54-05:00,"Myriad Genetics EPS in-line, misses on revenue",No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-01-07 13:52:41-05:00,Myriad Genetics down 11% on bearish reports,No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-01-07 13:52:41-05:00,Myriad Genetics down 11% on bearish reports,No summary available.,"MYD,MYGN",en,Seeking Alpha
2019-01-03 13:43:46-05:00,Needham sees 27% upside in Thermo Fisher in today's analyst action,No summary available.,"MYD,MYGN",en,Seeking Alpha
